Travere Therapeutics, Inc. revenue by segment TVTX

Annual Quarterly

Travere Therapeutics, Inc. splits its revenue into 7 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was FILSPARI at $322.0 million, 66% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2026 Sep 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Revenue	651	491	233	145	109	132	198	175	164	—	—
FILSPARI	550 +104.9% share 84.4%	322 +143.5% share 65.6%	132 +352.7% share 56.7%	29 share 20.1%	—	—	—	—	—	—	—
Product	—	—	—	—	98 -14.9% share 89.5%	115 share 87.3%	—	—	—	—	—
Bile Acid Products	—	—	—	—	—	96 +7.0% share 72.6%	89 +12.2% share 45.1%	80 +6.2% share 45.5%	75 +3.4% share 45.7%	73	—
Tiopronin Products	83 -7.0% share 12.7%	88 -6.4% share 18.0%	94 -3.9% share 40.5%	98 +0.4% share 67.7%	98 -14.9% share 89.5%	115 +5.7% share 87.3%	109 +13.8% share 54.9%	96 +7.2% share 54.5%	89 +8.3% share 54.3%	82	—
License	18 -76.6% share 2.8%	80 +1141.0% share 16.4%	6 share 2.8%	—	11 -31.3% share 10.5%	17 share 12.7%	—	—	—	—	—
Clinical Development Activity	—	—	—	14 share 9.9%	—	—	—	—	—	—	—
Active Pharmaceutical Ingredient	—	—	—	3 share 2.3%	—	—	—	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: TVTX (Nasdaq)
Fiscal year ends: December 31
Incorporated in: CA
Headquarters: San Diego, CA
SEC filer status: Large accelerated filer
SEC CIK: 1438533
Former names: Retrophin, Inc. (until Nov 13, 2020); Desert Gateway, Inc. (until Feb 19, 2013)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.